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Sumnnary Production of colony-stimulating factor (CSF) was examined in three patients with lung cancer
associated with neutrophilia. All three patients presented a marked increase in neutrophil count
(26,000-39,000 l-') that continued at least for 3 weeks and rapidly disappeared after surgical removal of the
tumours. Culture media (CM) incubated with the excised tumour tissues stimulated the colony formation of
bone marrow myeloid progenitor cells in vitro. Northern blot analysis of poly(A)+ RNA from the tumour
tissues revealed a constitutive expression of granulocyte (G), macrophage (M), and granulocyte-macrophage
(GM) CSF genes in all tumours. Immunoassay specific for these CSFs revealed that G- and M-CSF
immunoreactivity was detected in all CM and GM-CSF protein in two out of three CM. The plasma CSF
levels also increased before operation and decreased to normal or near-normal range after operation. In
contrast, tumour cell CM obtained from two lung cancer patients without leucocytosis neither stimulated
haematopoietic colony formation nor contained immunoreactive CSFs. These results indicated that the
neutrophilia found in the three patients was probably caused by constitutive production of multiple CSFs by
lung cancer cells.
Leucocytosis is a well-recognised haematological abnormality
that develops in cancer patients. Although several mechan-
isms responsible for this morbidity can be speculated, recent
studies have revealed that production of leucopoietic factors
is the major cause of this paraneoplastic syndrome (Asano et
al., 1977; Sata et al., 1979; Suda et al., 1980).
The leucopoietic factors are now called colony-stimulating
factor (CSF), and there are at least four kinds of human
CSFs: granulocyte (G) CSF, macrophage (M) CSF, granulo-
cyte macrophage (GM) CSF and interleukin 3. All of these
CSFs have been purified and their cDNAs molecularly
cloned and sequenced (Kawasaki et al., 1985; Nagata et al.,
1986; Wong et al., 1985; Yang et al., 1986). These CSFs have
been demonstrated in vitro to act on haematopoietic stem
cells and progenitor cells at different stages of differentiation
to stimulate self-renewal and differentiation of haemato-
poietic cells. Furthermore, the in vivo administration of
recombinant CSF proteins revealed that these proteins are
active in vivo and have a potent activity to increase the
neutrophils (Antman et al., 1988; Cebon et al., 1988;
Masaoka et al., 1989; Morstyn et al., 1989).
In the present study, we attempted to characterise and
identify factors with colony-stimulating activity produced by
lung cancer cells to elucidate the involvement of CSFs in
cancer-associated neutrophilia. Northern blot analysis and
specific immunoassay revealed that constitutive production of
multiple CSFs synergistically increased the neutrophil count
in three patients with lung cancer.
Materials and methods
Cell culture
Tumour tissues were obtained at surgical operation with
informed consent. All three patients presented remarkable
neutrophilia at least for 3 weeks, and antibiotic therapy did
not decrease the neutrophil count. The clinical features of
three patients with lung cancer associated with neutrophilia
and two patients wihout neutrophilia used as negative con-
trols are described in Table I. Approximately 3 g of tumour
tissue was aseptically minced into small pieces and cultured
for 72 h in RPMI-1640 medium (Gibco, NY, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco) and
100 U ml penicillin G and 100 figml streptomycin. The
conditioned media (CM) were centrifuged at 400 g for
20 min. The supernatant was passed through a 0.45-ytm Mil-
lipore filter (Millipore, Bedford, MA, USA) and then freeze
preserved at - 20°C until used for colony-forming assay and
immunoassay. A part of the tumour tissue was stored in
liquid nitrogen for poly(A)+ RNA extraction. As negative
controls, tissue from two lung cancer patients without neu-
trophilia was obtained at surgery with informed consent and
treated as described above. As a positive control,
mononuclear cells isolated from peripheral blood using
Ficoll-Hypaque density-gradient centrifugation (specific
gravity 1.077; Pharmacia LKB, Uppsala, Sweden) were cul-
tured in RPMI-1640 medium supplemented with 10% FBS
and 10ttgml-' concanavalin A (con A; Seikagaku Kogyo,
Osaka, Japan) for 72h. The supernatant was used for
colony-forming assay and the cell pellet for extracting
poly(A)+ RNA.
Bioassayfor colony-stimulating activity
Bone marrow cells were obtained from a healthy volunteer
with informed consent. Mononuclear cells were isolated by
density-gradient centrifugation on Ficoll-Hypaque and were
depleted of adherent cells by 2 h incubation in plastic culture
dishes. The non-adherent cells were cultured at a concentra-
tion of 2 x I0O cells ml-' with McCoy 5A medium (Gibco)
containing 20% (v/v) FBS, 20% (v/v) CM and 0.3% (w/v)
agar at 37°C in a 5% carbon dioxide humidified atmosphere.
After incubation for 14 days the number of colonies (cell
aggregates more than 40 cells) was counted under an inverted
microscope.
Northern blot analysis
Poly(A)+ RNA extraction, gel electrophoresis and Northern
blot hybridisation were done by the methods reported
previously (Suzuki et al., 1987). Briefly, tumour tissues and
cultured cells were homogenised in guanidine thiocyanate
and subjected to ultracentrifugation through a caesium
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Table I Clinical data of five patients with lung carcinoma
Patient I Patient 2 Patient 3 Patient 4 Patient S
Age (years) 46 83 57 72 56
Sex Male Female Male Male Female
Tumour size (cm) 4.0 x 3.3 x 2.8 4.2 x 3.5 x 2.5 5.6 x 4.0 x 3.4 4.8 x 3.5 x 2.9 6.0 x 5.1 x 3.9
Pathology Large cell Squamousa Squamousa Squamous Adeno
WBC count (sl-') 44,100 (9,700) 38,100 (6,800) 31,400 (7,600) 8,200 5,600
Neutrophil (%) 89 (48) 85 (52) 83 (55) 43 51
Monocyte (%) 6 1 5 4 6
Eosinophil (%) 1 2 1 2 4
aSquamous cell carcinoma with giant cell component. Values in parentheses are white blood cell count and
percentage of neutrophil 3 weeks after surgical operation.
chloride gradient. The RNA pellet dissolved in 10 mM
Tris-HCl (pH 7.4) containing 1 mM EDTA was applied to
an oligo(dT)-cellulose column (Collaborative Research, Bed-
ford, MA, USA) to isolate poly(A)+ RNA. For detecting
human CSF mRNA, oligonucleotide probes were chemically
synthesised by a DNA synthesiser (Applied Biosystems, CA,
USA). These oligonucleotides were complementary to
mRNA encoding mature G-, GM- and M-CSF protein. A
probe of 39 bases in length for detecting P-actin mRNA was
also synthesised to examine the integrity and compare the
applied amount of mRNA in each sample. The DNA se-
quence of the synthetic probes is given in Figure 1. A
20 pmol aliquot of these synthetic probes was labelled at the
5' end with 40 pmol of [y-32P]ATP (5,000 Ci mmol ', Amer-
sham International, UK) by T4 polynucleotide kinase (Boeh-
ringer Mannheim, Germany). The specific activities of the
probes were about 2 x 106 c.p.m. pmol '. The poly(A)+
RNA from samples was electrophoresed on 1.2% formalde-
hyde-agarose gels and then transferred to nitrocellulose
filters. Hybridisation was performed at 42°C for 24 h.
Immunoassay
The method for enzyme immunoassay (EIA) for G-CSF has
been described previously (Motojima et al., 1989). The EIA
kit for GM-CSF was purchased from Genzyme (Boston,
MA, USA). Radioimmunoassay (RIA) for M-CSF was
developed using rabbit antiserum against recombinant
human M-CSF (rhM-CSF). rhM-CSF was iodinated using
lodo-gen by the method reported by Franker & Speck
(1978). For quantitation of immunoreactive (IR)-M-CSF,
100111 of sample, 100fl of [I251]M-CSF
(10,000 c.p.m. 100111-) and 200 il of anti-M-CSF antibody
(1:40,000 dilution) were mixed and incubated at room
temperature for 24 h. For separation of bound and free
[125I]M-CSF, 100,l of normal rabbit serum, 100 ,LI of anti-
rabbit IgG serum and 200itl of 12.5% polyethylene glycol
6000 were added and centrifuged at 3,000 r.p.m. for 15 min
at 4°C. Then the supernatant was removed and the
precipitate counted by an automatic gamma-counter.
Results
Colony-stimulating activity in tumour cell CM
Colony-stimulating activity was detected in all CM from the
three tumour tissues associated with neutrophilia, without
concentration or dialysis. In contrast, CM from the tumour
tissues from patients without neutrophilia did not stimulate
colony formation (Table II). Since non-adherent cells were
used in this assay, colony-stimulating activity in CM was
attributed to the activity of CSFs, but not to the activities
that stimulate the adherent cells to produce the endogenous
CSFs.
Northern blot analysis
The results of Northern blot analysis are shown in Figure 2.
G-CSF mRNA was detected in all three tumours associated
G-CSF 5'- TTG CTC TAA GCA CTT GAG CAG GAA GCT CTG GGG CAG GGA
GCT GGC AGG GCC CAG GGG GGT -3'
M-CSF 5'- CCC TAT AAT CTC CTT GAC AAT AGA GCT GCA ATT CAA CGT
TCT GGT TAA ACG GTG GGT ATC -3'
GM-CSF 5'- GGG TGC AGA GAT GCT GCA GGC CAC AGT GCC CAA GAG CAG
CAG GCT CTG CAG CCA CAT - 3'
P-Actin 5'- TTC TAC TGG GTC TAG TAC AAA CTC TGG AAG TTG TGG GGT -3'
Figure 1 DNA sequence of synthetic oligonucleotide probes
used for detection of colony-stimulating factor and P-actin
mRNA. G-CSF, granulocyte colony-stimulating factor; M-CSF,
macrophage colony-stimulating factor; GM-CSF, granulo-
cyte-macrophage colony-stimulating factor.
Table II Number of colonies stimulated by tumour cell culture
medium
CM source Number ofcolonies/2 x 105 cells
Patient 1 31.0 ± 3.0
Patient 2 64.8 ± 4.2
Patient 3 38.8± 3.1
Patient 4 0.5 ± 0.5
Patient 5 0.5 0.5
Mediuma 0.5±0.5
aRPMI-1640 medium plus 10% fetal bovine serum.
with neutrophilia. The molecular size of G-CSF transcript
was about 1.7 kb and appeared to be identical to that of con
A-stimulated mononuclear cells. M-CSF mRNA was also
detected in the three tumour cells. Two major bands, 4.2 kb
and 3.8 kb, were observed in all tumour cells, but the inten-
sity of the hybridisation band in patient 3 was faint. In
contrast, no CSF gene transcript was detected in tumour cells
from patients without neutrophilia. When the probe for P-
actin was used, a hybridisation band with molecular size of
2.0 kb was observed in all samples with slight variation in
intensity.
IR-G-CSF, IR-M-CSFand IR-GM-CSF in CM andplasma
IR-G-CSF, M-CSF and GM-CSF were detected in all three
CM associated with neutrophilia except IR-GM-CSF in
patient 3 (in whom GM-CSF mRNA was also faint). The
IR-G-CSF and GM-CSF levels in plasma also increased in
patients with neutrophilia. Since the colony-forming assay
using authentic G-CSF and GM-CSF proteins showed that
50-100 pgml' of each CSF protein was enough to
stimulate the haematopoietic colony formation (data not
shown), the concentration of IR-G-CSF and GM-CSF in
plasma from patients with neutrophilia was high enough to
stimulate the proliferation of the myeloid progenitor cells. In
contrast, in patients without neutrophilia, IR-G-CSF and
GM-CSF levels were below the detection limit in CM and
plasma. IR-M-CSF was detected only in CM from the
patients with neutrophilia. The plasma IR-M-CSF level in
patients with neutrophilia was also higher than that inMULTIPLE CSF PRODUCTION IN LUNG CANCER CELLS 127
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Figure 2 Northern hybridisation analysis ofCSFmRNA. Aliquots of5 tLgofpoly(A)+ RNA from con A-stimulated mononuclear cells
(lane 1), patient 1 (lane 2), patient 2 (lane 3), patient 3 (lane 4), patient 4 (lane 5) and patient 5 (lane 6) electrophoresed on
formaldehyde-agarose gels, hybridised with synthetic G-CSF probe (a), GM-CSF probe (b), M-CSF probe (c) and P-actin (d). G-CSF,
granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage colony-
stimulating factor.
patients without neutrophilia, which remained in the normal
range reported previously (Kimura et al., 1992) (Tables III
and IV).
Discussion
The aetiology of leucocytosis in lung cancer patients may
differ from patient to patient. It may be caused by con-
comitant infection, tumour necrosis, steroid administration
or production of leucopoietic factors by tumour cells. Leuco-
cytosis is a not uncommon paraneoplastic syndrome in lung
cancer patients: in one retrospective study, Ascensao et al.
Table III Immunoreactive G-, M- and GM-CSF concentration in
culture medium
IR-G-CSF IR-M-CSF IR-GM-CSF
CM source (ng ml ') (ng ml-') (ngml-')
Patient 1 0.97 2.08 1.15
Patient 2 3.01 0.47 <0.01
Patient 3 0.85 1.57 1.30
Patient 4 <0.06 <0.1 <0.01
Patient 5 <0.06 <0.1 <0.01
Mediuma <0.06 <0.1 <0.01
aRPMI-1640 medium plus 10% fetal bovine serum. CM, culture
medium; IR, immunoreactive; G-CSF, granulocyte colony-stimulating
factor; M-CSF, macrophage colony-stimulating factor; GM-CSF,
granulocyte-macrophage colony-stimulating factor.
(1987) reported that 43 out of 105 patients with non-small
cell lung cancer had leucocytosis, and in 13 of the 43 patients
absolute neutrophilia was noted and the aetiology was attri-
buted to the tumour itself. Although colony-stimulating
activity was not examined in this study, neutrophilia caused
by CSF production from tumour cells may not be rare in
lung cancer patients.
In the present study, three patients with lung cancer
developed remarkable leucocytosis, ranging from 31,400 to
44,100fl-1, and 83-89% of leucocytes in the peripheral
blood were mature neutrophils. Infection or chronic
myelocytic leukaemia was ruled out by the laboratory
examinations. The neutrophil count decreased to normal
range after surgical resection of the tumour within 2-3 weeks
in all cases. Furthermore, when the tumour recurred in
patients 1 and 2, remarkable neutrophilia (25,000 and
19,00014l'1 respectively) was again observed. These clinical
observations indicate that the neutrophilia of these patients
was dependent on the presence of tumour cells.
In the tumours associated with neutrophilia, constitutive
expression of G-, M- and GM-CSF genes was noted, and the
corresponding CSF protein production was detected by
specific immunoassays except GM-CSF protein in patient 3.
The molecular size of each CSF transcript appears to be
identical to that of con A-stimulated lymphocytes, indicating
that gross rearrangement of CSF genes does not occur and
that CSFs produced by tumour cells are probably identical to
normal CSFs. This result is compatible with the fact that
IR-CSFs in all cases are biologically active. It seems unlikely
Table IV G-CSF, M-CSF and GM-CSF levels in plasma before and after surgery
G-CSF (pgml-') M-CSF (ngml-') GM-CSF (pgml-')
Before After Before After Before After
Patient 1 65.3 UD 7.1 1.6 NT NT
Patient 2 193.6 UD 5.6 2.5 UD UD
Patient 3 102.4 UD 5.3 0.9 78.4 12.5
Patient 4 UD UD 4.3 NT UD UD
Patient 5 UD UD 3.3 NT UD UD
The detection limit ofG-, M-, GM-CSF immunoassay was 10 pg ml-', 0.1 ngml-' and
10pgml-' respectively. G, granulocyte; M, macrophage; GM, granulocyte-macro-
phage; CSF, colony-stimulating factor; UD, undetectable; NT, not tested.
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that these CSFs were derived from host monocytes or macro-
phages infiltrating the tumours because these cells were
microscopically few in number and the same amount of
mononuclear cell infiltration was observed in tumour cells
from patients without neutrophilia. Furthermore, inter-
leukins la and lp and tumour necrosis factor-a, representa-
tive monokines that are produced by activated monocytes
and macrophages, were below the detection limit in all
tumour cell CM from patients with neutrophilia (data not
shown). These results indicated that monocyte/macrophage
infiltration into the tumours was unlikely to be responsble for
the majority of the CSFs recovered from the tumour
CM.
We therefore interpret our data as showing that lung
cancers constitutively produce multiple CSFs. Although
induced production of more than two kinds of CSFs has
been demonstrated in T lymphocytes, fibroblasts and bone
marrow stromal cells (Wong et al., 1985; Yang et al., 1986;
Rennick et al., 1987; Kaushansky et al., 1988), there are few
reports in which primary tumour cells constitutively produce
multiple CSFs. Since the effect of CSF on the haematopoietic
colony formation is synergistic in vitro (Metcalf, 1984), it is
reasonable to speculate that tumour-producing CSFs syner-
gistically increase the neutrophil count in patients with
tumours. The mechanism of constitutive production of CSF
by tumour cells is not clear. However, there are no reports
describing CSF gene rearrangement or gene amplification,
and induction of trans-activating factors which enhance CSF
gene transcription is now speculated. Recently, Miyatake et
al. (1988) reported that a conserved DNA sequence was
found in the promoter region of GM-CSF gene, and this
sequence was involved in GM-CSF gene expression by p4Ox
protein, which is a trans-activating DNA-binding protein
produced by human T-cell leukaemia virus type I (HTLV-I)-
infected cells. Interestingly, the same sequence (GAGRTTC-
CAC) is also found in the promoter region of G-CSF and
IL-3 (Tsuchiya et al., 1987). These reports suggest the pos-
sibility that a common DNA-binding protein which happens
to be produced in the lung cancer cells induces the simul-
taneous production of multiple CSFs.
The biological significance of tumour-producing CSFs has
not been fully elucidated. There are reports demonstrating
that CSF receptors are expressed in non-haematological
tumours and that CSF enhances the growth and metastasis
of the tumours (Horiguchi et al., 1988; Baldwin et al., 1989;
Berdel et al., 1989). Furthermore, it is suggested that neutro-
phils increased by tumour-producing CSF facilitate tumour
growth and metastasis directly (Milas et al., 1984; Aeed et
al., 1988; Welch et al., 1989) or indirectly by suppressing
cellular immunity through induction of suppressor macro-
phages (Tsuchiya et al., 1988) or through suppression of
killer cell induction (Seaman et al., 1982; Shau & Kim, 1988;
Shau & Golub, 1989). Indeed, two reports demonstrate that
G-CSF treatment reduces the antitumour effect of interferon
in vivo (Quesada et al., 1983; Segawa et al., 1991). Therefore
both CSF itself and neutrophils increased by CSF may exert
an adverse effect on the clinical course of the patients with
CSF-producing tumours. Further study will be needed to
elucidate the biological significance of tumour-producing
CSF on the clinical course of the patients.
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